Although the low concentration ratios of brain-to-plasma for EGFR-TKIs (< 1–3%) have been reported, several prospective studies have shown that the treatment of EGFR-TKIs has a positive activity in NSCLC patients with multiple BM and EGFR mutation, with a response rate of up to 80% [21–23]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.